National Patent Development Corp Bar-Ilan University Israel said joint venture corporation , Scientific Testing Inc , begin clinical trial U.S. immuno-augmenting compound , AS101 , treatment Acquired Immune Deficiency Syndrome ( AIDS ) .
The study conducted Institute Immunological Disorders ( MD Anderson Hospital , Houston , Tex ) direction Dr Peter Mensell , pursuant investigational new drug application filed Food Drug Administration , company said .
The study , expected begin four six week , designed test effect AS101 30 AIDS patient , National Patent said .
It added AS101 , proprietary synthetic compound invented Bar-Ilan University doctor , shown immuno-augmenting , anti-viral anti-tumor activity preclinical animal testing , immuno-augmenting activity limited number AIDS patient phase one foreign clinical test .
Reuter & # 3 ; 